Our In Vivo Approach - Castle Creek Biosciences, Inc. : Castle Creek Biosciences, Inc.

About
Technology
Pipeline
- D-Fi Gene Therapy for Dystrophic Epidermolysis Bullosa (DEB)
Patients & Families
- Epidermolysis Bullosa (EB)

Contact Us

Press Releases

Our In Vivo Approach

May 2, 2022

Our In Vivo Approach

Recent Posts

Castle Creek Biosciences Announces Publication of Preclinical Study for Potential In Vivo Gene Therapy in Nature Communications
Castle Creek Biosciences Raises $112.8 Million to Advance Novel Gene Therapies and Expand Pipeline
American Society of Gene & Cell Therapy (ASGCT) Annual Meeting Hybrid Conference
Society of Investigative Dermatology (SID) Annual Meeting

Castle Creek Biosciences, Inc.
405 Eagleview Boulevard
Exton, PA 19341

Connect with us:

©2024 Castle Creek Biosciences, Inc. All Rights Reserved. The registered dual crescent logo and “Castle Creek Biosciences” are trademarks of Castle Creek Biosciences, LLC.

Privacy Policy | Terms of Use